Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02735707 |
Recruitment Status :
Recruiting
First Posted : April 13, 2016
Last Update Posted : June 5, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.
The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.
In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.
REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Community-acquired Pneumonia, Influenza, COVID-19 | Drug: Ceftriaxone Drug: Moxifloxacin or Levofloxacin Drug: Piperacillin-tazobactam Drug: Ceftaroline Drug: Amoxicillin-clavulanate Drug: Standard course macrolide Drug: Extended course macrolide Other: No systemic corticosteroid Drug: Fixed-duration Hydrocortisone Drug: Shock-dependent hydrocortisone Drug: Fixed-duration higher dose Hydrocortisone Other: No antiviral agent for influenza Drug: Five-days oseltamivir Drug: Ten-days oseltamivir Other: No antiviral agent for COVID-19 Drug: Lopinavir / Ritonavir Drug: Hydroxychloroquine Drug: Hydroxychloroquine + lopinavir/ritonavir Drug: Ivermectin Other: No immune modulation for COVID-19 Drug: Interferon beta-1a Drug: Anakinra Drug: Tocilizumab Drug: Sarilumab Drug: Local standard venous thromboprophylaxis Drug: Therapeutic dose anticoagulation Drug: Conventional low dose thromboprophylaxis Drug: Intermediate dose thromboprophylaxis Drug: Continuation of therapeutic dose anticoagulation Other: No immunoglobulin Biological: Convalescent plasma Biological: Delayed administration of convalescent plasma Other: No vitamin C Drug: Vitamin C Other: No antiplatelet Drug: Aspirin Drug: P2Y12 inhibitor Other: No simvastatin Drug: Simvastatin Other: Placebo Drug: Eritoran Drug: Apremilast Procedure: Clinician-preferred mechanical ventilation strategy Procedure: Protocolised mechanical ventilation strategy Other: No renin-angiotensin system inhibitor Drug: Angiotensin converting enzyme inhibitor Drug: Angiotensin Receptor Blockers Drug: ARB + DMX-200 Other: No cysteamine Drug: Cysteamine Drug: Fixed-duration dexamethasone Drug: Baloxavir Marboxil Drug: Five-days oseltamivir + baloxavir marboxil Drug: Ten-days oseltamivir + baloxavir marboxil Other: No endothelial modulator Drug: Imatinib | Phase 3 |
Community-acquired pneumonia (CAP) that is of sufficient severity to require admission to an intensive care unit (ICU) is associated with substantial mortality.
Patients with pneumonia who are being treated in an ICU will receive therapy that consists of many different treatments, as many as 20 or 30. These treatments act together to treat both the infection and its effects on the body. When treating a patient, doctors choose from many different treatments, most of which are known or believed to be safe and effective. However, doctors don't always know which treatment option is the better one, as individuals or groups of individuals may respond differently. This study aims to help doctors understand which treatments work best.
This clinical study has been designed in a way that allows the information from patients already in the study to help new patients joining the study. Most studies aren't able to do that. REMAP-CAP has been designed to:
- Evaluate multiple treatment strategies, at the same time, in the same patient.
- Reach platform conclusions when sufficient data is accrued, rather than when a pre-specified sample size is reached
- Utilise data that is already accrued to increase the likelihood that patients within the trial are randomised to treatments that are more likely to be beneficial
- New questions can be substituted into the trial as initial questions are answered, meaning that the trial can be perpetual or open-ended
- Interactions between interventions in different domains can be evaluated
It is reasonable to presume that any pandemic respiratory infection of major significance to public health will manifest as life-threatening respiratory infection including Severe Acute Respiratory illness and severe Community Acquired Pneumonia (CAP) with concomitant admission to hospital, and for some patients, admission to an Intensive Care Unit (ICU). Previous pandemics and more localized outbreaks of respiratory emerging infections have resulted in severe CAP and ICU admission.
Previous pandemics and outbreaks of emerging infectious diseases have outlined the urgent need for evidence, preferably from Randomized Controlled Trials (RCTs), to guide best treatment. However, there are substantial challenges associated with being able to organize such trials when the time of onset of a pandemic and its exact nature are unpredictable. As an adaptive platform trial that enrolls patients during the interpandemic period, REMAP-CAP is ideally positioned to adapt, in the event of a respiratory pandemic, to evaluate existing treatments as well as novel approaches.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 10000 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Intervention Model Description: | Adaptive Bayesian Platform Trial evaluating multiple interventions in multiple domains |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia |
Actual Study Start Date : | April 11, 2016 |
Estimated Primary Completion Date : | February 2026 |
Estimated Study Completion Date : | February 2028 |

Arm | Intervention/treatment |
---|---|
Antibiotic Domain
Patients with community-acquired pneumonia admitted to participating intensive care units and requiring empiric antibiotic therapy will be randomised one of five antibiotic interventions. Note: the ceftaroline + macrolide intervention has been closed to recruitment. |
Drug: Ceftriaxone
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice. Drug: Moxifloxacin or Levofloxacin The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice. Drug: Piperacillin-tazobactam The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice. Drug: Ceftaroline The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice. Drug: Amoxicillin-clavulanate The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice. |
Macrolide Duration Domain
Patients with community-acquired pneumonia admitted to participating intensive care units who have been allocated to a beta-lactam antibiotic intervention in the Antibiotic Domain will be randomised to either a standard course or extended course of macrolide therapy
|
Drug: Standard course macrolide
Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5. The dosing of and route of administration is not protocolised, the following guidance is provided:
Drug: Extended course macrolide Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first). The dosing of and route of administration is not protocolised, the following guidance is provided:
|
Corticosteroid Domain
Patients with community acquired pneumonia (CAP) admitted to participating intensive care units will be randomised to a steroid use strategy. Note: this domain is now closed to patients with suspected or proven COVID-19. It remains open to patients with CAP without COVID-19. |
Other: No systemic corticosteroid
Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first). Drug: Fixed-duration Hydrocortisone 50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days. Drug: Shock-dependent hydrocortisone 50mg IV hydrocortisone every 6 hours while the patient is in septic shock Drug: Fixed-duration higher dose Hydrocortisone 100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days. Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed. Drug: Fixed-duration dexamethasone 6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital. |
Influenza Antiviral Domain
Patients with community-acquired pneumonia admitted to participating intensive care units with microbiological testing confirmed influenza infection will be randomised to one of six interventions.
|
Other: No antiviral agent for influenza
No antiviral agent intended to be active against influenza infection is to be administered Drug: Five-days oseltamivir Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first) Drug: Ten-days oseltamivir Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first) Drug: Baloxavir Marboxil Baloxavir marboxil administered on days 1 and 4 post-randomisation. Drug: Five-days oseltamivir + baloxavir marboxil Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation. Drug: Ten-days oseltamivir + baloxavir marboxil Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation. |
COVID-19 Antiviral Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to no ivermectin or ivermectin. Note: an earlier version of this domain evaluated lopinavir-ritonavir, hydroxychloroquine, and combination lopinavir-ritonavir and hydroxychloroquine against a 'no antiviral' control. This domain is now closed. |
Other: No antiviral agent for COVID-19
No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered Drug: Lopinavir / Ritonavir Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU. Note: this intervention is now closed. Drug: Hydroxychloroquine Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first). Note: this intervention is now closed. Drug: Hydroxychloroquine + lopinavir/ritonavir Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU. Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first). Note: this intervention is now closed. Drug: Ivermectin Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day. |
COVID-19 Immune Modulation Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five interventions. Note: this domain is now closed. |
Other: No immune modulation for COVID-19
No immune modulating agent intended to be active against COVID-19 is to be administered. Note: this intervention is now closed. Drug: Interferon beta-1a IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first. Note: this intervention is now closed. Other Name: IFN-β1a Drug: Anakinra A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours. In patients with renal impairment, anakinra will be administered on alternate days. Note: this intervention is now closed. Drug: Tocilizumab Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. Note: this intervention is now closed. Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period. Drug: Sarilumab Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period. Note: this intervention is now closed. |
Anticoagulation Domain
Patients admitted to participating intensive care units with suspected or microbiological testing confirmed COVID-19 will be randomised to an anticoagulation strategy. Note: A previous version of this domain evaluated local standard venous thromboprophylaxis against therapeutic dose anticoagulation. |
Drug: Local standard venous thromboprophylaxis
Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Note: this intervention is now closed. Drug: Therapeutic dose anticoagulation Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician. Note: this intervention is now closed. Drug: Conventional low dose thromboprophylaxis Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain. Drug: Intermediate dose thromboprophylaxis Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain. Drug: Continuation of therapeutic dose anticoagulation Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first. |
Immunoglobulin Domain
Immunosuppressed patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive no immunoglobulin for COVID-19, or to receive high-titre convalescent plasma. Note: an earlier version of this domain was not restricted to immunosuppressed patients. |
Other: No immunoglobulin
No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered. Note: this intervention is now closed. Biological: Convalescent plasma Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation. Note: this intervention is now closed. Biological: Delayed administration of convalescent plasma Note: this intervention is now closed. |
Vitamin C Domain
Patients admitted to participating hospitals with community-acquired pneumonia will be randomised to receive no vitamin C, or vitamin C. Note: this domain is now closed. |
Other: No vitamin C
No high dose intravenous vitamin C is to be administered Drug: Vitamin C Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses |
Simvastatin Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no simvastatin, or simvastatin. Note: this domain is now closed. |
Other: No simvastatin
No simvastatin intended to be active against COVID-19 is to be administered Drug: Simvastatin Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation |
Antiplatelet Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no antiplatelet, aspirin, or site-preferred P2Y12 inhibitor.
|
Other: No antiplatelet
No antiplatelet agent or NSAID to be administered. Note: this intervention is now closed. Drug: Aspirin Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed. Other Name: acetylsalicylic acid Drug: P2Y12 inhibitor Site-selected P2Y12 inhibitor:
Note: this intervention is now closed. Other Names:
|
Mechanical Ventilation Domain
Patients with community-acquired pneumonia admitted to participating intensive care units who are intubated and receiving invasive mechanical ventilation will be randomised to protocolised mechanical ventilation strategy, or clinician-preferred mechanical ventilation strategy
|
Procedure: Clinician-preferred mechanical ventilation strategy
Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters Procedure: Protocolised mechanical ventilation strategy Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain. |
COVID-19 Immune Modulation (2) Domain
Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive one of three interventions. Note: this domain is now closed. |
Other: Placebo Drug: Eritoran Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital Drug: Apremilast Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed. |
ACE2 RAS Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five renin-angiotensin system blockade strategies. Note: this domain is now closed. |
Other: No renin-angiotensin system inhibitor
No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10. Drug: Angiotensin converting enzyme inhibitor Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.
Other Names:
Drug: Angiotensin Receptor Blockers Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.
Other Names:
Drug: ARB + DMX-200 Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first. ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily. |
Cysteamine Domain
Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no cysteamine, or cysteamine.
|
Other: No cysteamine
No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first. Drug: Cysteamine Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first. |
Endothelial Domain
Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no endothelial modulator or enteral imatinib.
|
Other: No endothelial modulator
No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered. Drug: Imatinib Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge. |
- All-cause mortality [ Time Frame: Day 90 ]
- Days alive and not receiving organ support in ICU [ Time Frame: Day 21 ]Primary end-point for patients with suspected or proven COVID-19 pandemic infection
- ICU Mortality [ Time Frame: Day 90 ]
- ICU length of stay [ Time Frame: Day 90 ]
- Hospital length of stay [ Time Frame: Day 90 ]
- Ventilator free days [ Time Frame: Day 28 ]
- Organ failure free days [ Time Frame: Day 28 ]
- All-cause mortality [ Time Frame: 6 months ]
- Health-related Quality of life assessment [ Time Frame: 6 months ]EQ5D-5L and WHODAS 2.0 (not completed in all regions)
- Proportion of intubated patients who receive a tracheostomy [ Time Frame: Day 28 ]
- Destination at time of hospital discharge [ Time Frame: Free text Day 90 ]Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital
- Readmission to the index ICU during the index hospitalization [ Time Frame: Day 90 ]
- World Health Organisation 8-point ordinal scale outcome [ Time Frame: Hospital discharge ]
- Occurrence of multi-resistant organism colonisation/infection [ Time Frame: Day 90, censored at hospital discharge ]Antibiotic Domain specific outcome
- Occurrence clostridium difficile [ Time Frame: Day 90, censored at hospital discharge ]Antibiotic Domain specific outcome
- Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death [ Time Frame: Day 90, censored at hospital discharge ]Macrolide Duration Domain specific outcome.
- Change from baseline influenza virus levels in upper and lower respiratory tract specimens [ Time Frame: Day 3, up to Day 7 ]Antiviral Domain specific outcome. Only required at selected sites.
- Confirmed deep vein thrombosis [ Time Frame: Between randomisation and hospital discharge ]Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.
- Confirmed pulmonary embolism [ Time Frame: Between randomisation and hospital discharge ]Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.
- Confirmed ischaemic cerebrovascular event [ Time Frame: Between randomisation and hospital discharge ]Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.
- Total red blood cell units transfused [ Time Frame: Between randomisation and end of study day 15 ]Domain-specific outcome for Anticoagulation and Antiplatelet Domains.
- Confirmed acute myocardial infarction [ Time Frame: Between randomisation and hospital discharge ]Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.
- Peak troponin [ Time Frame: Between randomisation and end of study day 15 ]Domain-specific outcome for Anticoagulation and Antiplatelet Domains.
- Major bleeding event [ Time Frame: Between randomisation and end of study day 15 ]Domain-specific outcome for Anticoagulation and Antiplatelet Domains.
- Other confirmed thrombotic event, including mesenteric ischaemia and limb ischaemia [ Time Frame: Between randomisation and hospital discharge ]Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.
- Acute kidney injury (KDIGO stage >= 2 acute kidney injury) [ Time Frame: Between randomisation and 7 days ]Domain-specific outcome for ACE2 RAS Domain
- Change from baseline to peak creatinine [ Time Frame: Between randomisation and 14 days ]Domain-specific outcome for ACE2 RAS Domain
- Angioedema [ Time Frame: Between randomisation and end of study day 12 ]Domain-specific outcome for ACE2 RAS Domain
- Change from baseline AST, ALT and bilirubin [ Time Frame: Between randomisation and 14 days ]Domain-specific outcome for ACE2 RAS Domain

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
REMAP-CAP PLATFORM INCLUSION CRITERIA:
-
Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with:
- symptoms or signs or both that are consistent with lower respiratory tract infection AND
- Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
-
Up to 48 hours after ICU admission, receiving organ support with one or more of:
- Non-invasive or Invasive ventilatory support;
- Receiving infusion of vasopressor or inotropes or both
PLATFORM EXCLUSION CRITERIA:
-
Healthcare-associated pneumonia:
- Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days
- Resident of a nursing home or long term care facility
- Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
- Previous participation in this REMAP within the last 90 days
REMAP-COVID PLATFORM INCLUSION CRITERIA
1. Adult patients (≥ 18 years) admitted to hospital with acute illness due to suspected or proven pandemic infection.
REMAP-COVID PLATFORM EXCLUSION CRITERIA
- Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
- Patient is expected to be discharged from hospital today or tomorrow
- More than 14 days have elapsed while admitted to hospital with symptoms of an acute illness due to suspected or proven pandemic infection.
- Previous participation in this REMAP within the last 90 days
DOMAIN-SPECIFIC ELIGIBLE CRITERIA:
Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02735707
Contact: Cameron Green, MSc | info@remapcap.org | ||
Contact: Svenja Peters, MSc | EU.remapcap@umcutrecht.nl |

Study Chair: | Steve Webb, Prof | Monash University, Study Chair REMAP-CAP Australia | |
Study Chair: | Colin McArthur, Dr | Medical Research Institute of New Zealand, Study Chair REMAP-CAP New Zealand | |
Study Chair: | Marc Bonten, Prof | UMC Utrecht, Study Chair REMAP-CAP Europe | |
Study Chair: | Lennie Derde, MD | UMC Utrecht, Coordinating Investigator REMAP-CAP Europe | |
Study Chair: | John Marshall, Prof | Unity Health Toronto, Study Chair REMAP-CAP Canada | |
Study Chair: | Derek Angus, Prof | University of Pittsburgh Medical Center, Study Chair REMAP-CAP USA |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Lennie Derde, Dr., UMC Utrecht |
ClinicalTrials.gov Identifier: | NCT02735707 |
Other Study ID Numbers: |
U1111-1189-1653 2015-002340-14 ( EudraCT Number ) 602525 ( Other Grant/Funding Number: European Union, FP7-HEALTH-2013-INNOVATION-1, PREPARE ) 16/631 ( Other Grant/Funding Number: Health Research Council of New Zealand ) APP1101719 ( Other Grant/Funding Number: National Health and Medical Research Council, Australia ) 158584 ( Other Grant/Funding Number: Canadian Institute of Health Research ) |
First Posted: | April 13, 2016 Key Record Dates |
Last Update Posted: | June 5, 2023 |
Last Verified: | June 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Pneumonia Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections Anti-Bacterial Agents Moxifloxacin Levofloxacin Antibiotics Hydrocortisone Anti-Infective Agents Ceftriaxone Piperacillin-tazobactam Ceftaroline Amoxicillin-clavulanate Oseltamivir |
COVID-19 Influenza Intensive care Critical care SARS-CoV-2 Vitamin C Therapeutic Anticoagulation Statin Invasive Mechanical Ventilation Convalescent plasma Eritoran Apremilast DMX-200 Ivermectin |
COVID-19 Pneumonia Pneumonia, Viral Respiratory Tract Infections Infections Virus Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Aspirin Vitamins Ascorbic Acid |
Interferons Ritonavir Lopinavir Interferon-beta Oseltamivir Interferon beta-1a Antiviral Agents Baloxavir Amoxicillin Moxifloxacin Hydroxychloroquine Levofloxacin Ivermectin Ceftriaxone Tazobactam |